Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665234 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
A Phase 3 study of Keratoconjunctivitis Sicca, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT02665234: Completed Phase 3 study of Keratoconjunctivitis Sicca, sponsored by Mimetogen Pharmaceuticals USA.
NCT02665234 is a Phase 3 study of Keratoconjunctivitis Sicca that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 400 participants, above the 138-participant average among 10 other Keratoconjunctivitis Sicca trials with a reported enrollment target (190% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02665234, a Phase 3 study of Keratoconjunctivitis Sicca, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
Primary Outcome
An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)
Conditions Studied
Interventions
- DRUG Placebo Ophthalmic Solution
- DRUG 1% Tavilermide Ophthalmic Solution
Study Locations (1)
California
- MIM-726 Investigational Site - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
What the finished NCT02665234 record still lists
NCT02665234 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 138-participant average among 10 other Keratoconjunctivitis Sicca trials with a reported enrollment target (190% higher).
The record links to 1 condition, with Keratoconjunctivitis Sicca appearing as the primary indexed condition, and to 2 interventions - of which Placebo Ophthalmic Solution is the first listed.
NCT02665234 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02665234 about?
NCT02665234 is a clinical study titled "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease". The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
What is the current status of trial NCT02665234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2016-01. Estimated completion is 2017-03.
What conditions does trial NCT02665234 study?
This clinical trial studies the following conditions: Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT02665234?
The interventions under investigation include: Placebo Ophthalmic Solution (DRUG), 1% Tavilermide Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02665234?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconjunctivitis Sicca
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02665234's enrollment target sits among peer trials
400 2nd of 10 the highest of 10 other Keratoconjunctivitis Sicca trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconjunctivitis Sicca trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
COMPLETED
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
COMPLETED · Phase 1
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia